BlackRock, Inc. has officially notified that its direct and indirect ownership in Orion Oyj, a Finnish pharmaceutical company, has exceeded the 5% threshold as of June 4, 2026. This includes shares held directly, indirectly, and through financial instruments, totaling just over 5% of Orion's shares. The disclosure is made under Finnish securities law, signaling BlackRock's increased stake in Orion, which could influence investor confidence and company governance. Orion is known for its development and marketing of human and veterinary medicines, with a strong focus on cancer and pain therapies.
Students from the Midwest region won top honors at the 2026 Midwest Youth Entrepreneurship Showcases and will compete at the National Youth Entrepreneurship Showcase in New York City this November. Their ventures include AI platforms, storytelling ap...
Toro Corp. announced the results of its shareholder election for a special dividend declared in April 2026. The dividend of $0.90 per share was paid on June 5, 2026, either in cash totaling about $3.8 million or in approximately 5.7 million common sh...
Douglas Dynamics, a leading North American manufacturer of work truck attachments, announced a quarterly cash dividend of $0.295 per share for the second quarter of 2026. The dividend will be paid on June 30, 2026, to shareholders recorded by June 16...
True Health, a Chinese medical technology company specializing in robotic puncture and ablation devices, has filed for an IPO in Hong Kong to raise funds for product development and market expansion. The company leads China's small but fast-growing p...
Micro Imaging Technology, Inc. (MIT) announced the acquisition of Cellmyx, a company known for its quality medical tools in cosmetic surgery and regenerative medicine. This acquisition complements MIT's recent purchase of SaltMed/SaltFacial, enhancin...
